All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – A new analysis of the various pull mechanisms that have been suggested to de-risk antibiotic development concluded that the proposed $1 billion market entry awards are not large enough to revitalize the whole antibiotic supply chain.